Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

PURPOSE: To report the final results of a phase 2 high-dose gene therapy clinical trial in choroideremia. METHODS: DESIGN: Phase 2 clinical trial. PARTICIPANTS: Six men (age 32-72 years) with genetically-confirmed advanced choroideremia. Patients received subfoveal injection of AAV2-REP1 (1011 genome particles in 0.1 mL) in the worse-sighted eye. OUTCOME MEASURES: Primary measure was best-corrected visual acuity (BCVA) change from baseline in the treated eye compared to the untreated eye. Secondary endpoints included change from baseline in microperimetry, fundus autofluorescence, and spectral-domain optical coherence tomography (OCT). Safety evaluations included adverse events, viral shedding in body fluids, and vector antibody responses. RESULTS: Baseline mean ETDRS BCVA was 65.3±8.8 (SD, range 56-77, 20/32-20/80) letters in the treated eyes and 77.0±4.2 (69-81, 20/25-20/40) letters in the untreated eyes. At two years, one treated eye improved by 10 letters and another by 5 letters, while one untreated eye improved by 4 letters. All other eyes were within 2 letters of baseline. Baseline microperimetry sensitivities in the treated eyes were poor (1.2±2.1 (0,5.1) dB) and showed no significant change. No serious adverse event occurred. Two patients developed an atrophic retinal hole in a non-functioning macular area where baseline OCT showed pre-existing thinning. Intraoperative microscope-integrated OCT allowed proper subretinal injection with avoidance of excessive foveal stretching and macular hole formation. CONCLUSIONS: Sustained improvement or maintenance of BCVA is achievable in choroideremia with high-dose AAV2-REP1 indicating BCVA is a viable primary outcome in advanced choroideremia. Choroideremia gene therapy delivered with intraoperative OCT has a good safety profile.

Original publication

DOI

10.1016/j.ajo.2018.09.012

Type

Journal article

Journal

Am J Ophthalmol

Publication Date

18/09/2018